Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 Genotypes and Warfarin Dosing
Warfarin is a widely used anticoagulant with a narrow therapeutic index and large
interpatient variability in the dose required to achieve target anticoagulation. Common …
interpatient variability in the dose required to achieve target anticoagulation. Common …
Applications of CYP450 testing in the clinical setting
CF Samer, KI Lorenzini, V Rollason, Y Daali… - Molecular diagnosis & …, 2013 - Springer
Interindividual variability in drug response is a major clinical problem. Polymedication and
genetic polymorphisms modulating drug-metabolising enzyme activities (cytochromes P450 …
genetic polymorphisms modulating drug-metabolising enzyme activities (cytochromes P450 …
Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF)
BF Gage, Y Yan, PE Milligan, AD Waterman… - American heart …, 2006 - Elsevier
BACKGROUND: Although warfarin and other anticoagulants can prevent ischemic events,
they can cause hemorrhage. Quantifying the rate of hemorrhage is crucial for determining …
they can cause hemorrhage. Quantifying the rate of hemorrhage is crucial for determining …
Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin
BF Gage, C Eby, JA Johnson, E Deych… - Clinical …, 2008 - Wiley Online Library
Initiation of warfarin therapy using trial‐and‐error dosing is problematic. Our goal was to
develop and validate a pharmacogenetic algorithm. In the derivation cohort of 1,015 …
develop and validate a pharmacogenetic algorithm. In the derivation cohort of 1,015 …
Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data
The discovery of six distinct polymorphisms in the genetic sequence encoding for the
cytochrome P450 2C9 (CYP2C9) protein has stimulated numerous investigations in an …
cytochrome P450 2C9 (CYP2C9) protein has stimulated numerous investigations in an …
Pharmacogenomics and individualized drug therapy
M Eichelbaum, M Ingelman-Sundberg… - Annu. Rev …, 2006 - annualreviews.org
Pharmacogenetics deals with inherited differences in the response to drugs. The best-
recognized examples are genetic polymorphisms of drug-metabolizing enzymes, which …
recognized examples are genetic polymorphisms of drug-metabolizing enzymes, which …
A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin
G D'Andrea, RL D'Ambrosio, P Di Perna, M Chetta… - Blood, 2005 - ashpublications.org
Patients require different warfarin dosages to achieve the target therapeutic anticoagulation.
The variability is largely genetically determined, and it can be only partly explained by …
The variability is largely genetically determined, and it can be only partly explained by …
The largest prospective warfarin-treated cohort supports genetic forecasting
M Wadelius, LY Chen, JD Lindh… - Blood, The Journal …, 2009 - ashpublications.org
Genetic variants of cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase
(VKORC1) are known to influence warfarin dose, but the effect of other genes has not been …
(VKORC1) are known to influence warfarin dose, but the effect of other genes has not been …
[HTML][HTML] Genetic determinants of response to warfarin during initial anticoagulation
Background Genetic variants of the enzyme that metabolizes warfarin, cytochrome P-450
2C9 (CYP2C9), and of a key pharmacologic target of warfarin, vitamin K epoxide reductase …
2C9 (CYP2C9), and of a key pharmacologic target of warfarin, vitamin K epoxide reductase …
Clinical consequences of cytochrome P450 2C9 polymorphisms
J Kirchheiner, J Brockmöller - Clinical Pharmacology & …, 2005 - Wiley Online Library
The gene coding for the cytochrome P450 (CYP) enzyme 2C9 (CYP2C9) carries numerous
inherited polymorphisms. Those coding for R144C (* 2) and I359L (* 3) amino acid …
inherited polymorphisms. Those coding for R144C (* 2) and I359L (* 3) amino acid …